Antagonistic Antibodies Targeting LAIR1 Enhance T Lymphocyte Activation and Promote Inflammatory Phenotypes in Myeloid Cells

Written By Lara Wilson

Huang T. et al. The Society for Immunotherapy of Cancer's (SITC) 36 Annual Meeting & Pre-Conference Programs, Washington D.C. November 10-14, 2021

Lara Wilson
Previous

Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer
Next

IO-202, a first-in-class LILRB4 antagonist antibody, activates dendritic cells and inhibits solid tumor growth in preclinical studies.